hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06309407, orgStudyIdInfo id: STUDY00024903, briefTitle: Dosimeter Location in Pain Physicians, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-23, primaryCompletionDateStruct date: 2023-04-21, completionDateStruct date: 2023-04-21, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Oregon Health and Science University, class: OTHER, descriptionModule briefSummary: The primary objective is to determine if there is a significant difference in radiation readings between dosimeters worn on the chest versus the hand of interventional pain management physicians and elucidate which dosimeter had higher readings.The secondary objective is to track incidences of physician glove breaches in both groups to assess if wearing hand dosimeters is associated with an increased risk of this event., conditionsModule conditions: RAD, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants were randomized to wear either chest dosimeters only or chest and hand dosimeters for the duration of the study in order to measure differences in radiation readings by each dosimeter location., primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ACTUAL, armsInterventionsModule interventions name: Hand Dosimeters, interventions name: Standard Practice, outcomesModule primaryOutcomes measure: Radiation Readings, secondaryOutcomes measure: Number of Glove Breach Events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Oregon Health & Science University, city: Portland, state: Oregon, zip: 97239, country: United States, geoPoint lat: 45.52345, lon: -122.67621, hasResults: False
protocolSection identificationModule nctId: NCT06309394, orgStudyIdInfo id: INCB99280-102, briefTitle: A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2024-06-03, completionDateStruct date: 2024-06-03, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Incyte Corporation, class: INDUSTRY, descriptionModule briefSummary: This study is being conducted to assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of \[14C\]INCB099280 in Healthy Male Participants., conditionsModule conditions: Healthy Participants, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 7, type: ESTIMATED, armsInterventionsModule interventions name: INCB099280, outcomesModule primaryOutcomes measure: Total recovery of radioactivity from urine and feces., primaryOutcomes measure: Percentage of total radioactive dose in Plasma, Urinary and Fecal Excretion, secondaryOutcomes measure: Pharmacokinetic (PK) in Plasma, secondaryOutcomes measure: PK for whole blood and plasma total radioactivity, secondaryOutcomes measure: Number of participants with Treatment Emergent Adverse Events (TEAEs), eligibilityModule sex: MALE, minimumAge: 35 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06309368, orgStudyIdInfo id: 003875, briefTitle: Ostomy Primary Closure With 0.1% Betaine/0.1% Polyhexanide Wound Irrigation Compared to Pursestring Closure, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: University of Nevada, Las Vegas, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare two types of closure in patients with ostomies that are ready for closure. The main questions it aims to answer are:1. Surgical site infection rates2. Patient quality of life3. Time to wound healingParticipants will undergo either complete ostomy wound closure after washing out the wound with Prontosan, or their ostomy wound will be closed using the Pursestring method, where the wound will be left partially open and allowed to heal from the inside out. Researchers will compare these two groups' outcomes (questions to be answered) as listed above., conditionsModule conditions: Surgical Site Infection, conditions: Wound Surgical, conditions: Colorectal Disorders, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants will be randomly assigned to one of the two treatment groups., primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: No masking. This is a non-blinded randomized controlled trial, enrollmentInfo count: 84, type: ESTIMATED, armsInterventionsModule interventions name: Primary Ostomy Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation, interventions name: Pursestring Closure, outcomesModule primaryOutcomes measure: Surgical Site Infection Rates, secondaryOutcomes measure: Acceptability of wound and scar healing by patient, secondaryOutcomes measure: Acceptability of wound and scar healing by patient, secondaryOutcomes measure: Acceptability of wound and scar healing by patient, secondaryOutcomes measure: Acceptability of wound and scar healing by patient, secondaryOutcomes measure: Wound healing, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Medical Center, status: RECRUITING, city: Las Vegas, state: Nevada, zip: 89102, country: United States, contacts name: Abigail W Cheng, MD, role: CONTACT, phone: 916-695-4159, email: abigail.cheng@unlv.edu, contacts name: Lance Horner, MD, role: CONTACT, phone: 7755445456, email: lance.horner@unlv.edu, contacts name: Ovunc Bardakcioglu, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Lance Horner, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Abigail W Cheng, MD, role: SUB_INVESTIGATOR, contacts name: Henry Krasner, BS, role: SUB_INVESTIGATOR, contacts name: Kavita Batra, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 36.17497, lon: -115.13722, hasResults: False
protocolSection identificationModule nctId: NCT06309355, orgStudyIdInfo id: YR001-A03, briefTitle: Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Hangzhou Yirui Pharmaceutical Technology Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in adult patients with mild to moderate atopic dermatitis, conditionsModule conditions: Atopic Dermatitis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: YR001 ointment, interventions name: Placebo, outcomesModule primaryOutcomes measure: The primary endpoint will be safety. Specifically, the primary endpoint will be the incidence of treatment-related AEs (TRAEs) through Day 50., secondaryOutcomes measure: all treatment-emergents AEs, secondaryOutcomes measure: Efficacy of YR001 Ointment, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: DelRicht Research, city: Baton Rouge, state: Louisiana, zip: 70809, country: United States, contacts name: Ira H Thorla, Doctor, role: CONTACT, geoPoint lat: 30.45075, lon: -91.15455, hasResults: False
protocolSection identificationModule nctId: NCT06309277, orgStudyIdInfo id: GLG-100X, briefTitle: A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Gilgamesh Pharmaceuticals, class: INDUSTRY, descriptionModule briefSummary: The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy., conditionsModule conditions: Major Depressive Disorder, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: GM-1020, outcomesModule primaryOutcomes measure: Incidence of treatment emergent adverse events, secondaryOutcomes measure: Montgomery-Åsberg Depression Rating Scale (MADRS) Change from baseline to 72 hours, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MAC Clinical Research, status: RECRUITING, city: Manchester, country: United Kingdom, contacts name: Gregory, role: CONTACT, geoPoint lat: 53.48095, lon: -2.23743, hasResults: False
protocolSection identificationModule nctId: NCT06309251, orgStudyIdInfo id: KetoSTrENgTH, briefTitle: Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-03-01, primaryCompletionDateStruct date: 2025-05-31, completionDateStruct date: 2026-05-31, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Danone Nutricia SpA Società Benefit, class: INDUSTRY, descriptionModule briefSummary: The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD.The main question\[s\] it aims to answer are:* does KD support adequate growth?* does KD improve clinical symptoms?* how does KD impact quality of life? Participants will be followed up as per clinical practice, conditionsModule conditions: Drug Resistant Epilepsy, conditions: Autism Spectrum Disorder, conditions: Chronic Migraine, conditions: Brain Tumor, Pediatric, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: ketogenic diet (as per clinical practice), outcomesModule primaryOutcomes measure: Nutritional adequacy, secondaryOutcomes measure: Nutritional adequacy, secondaryOutcomes measure: % of responders to KD, secondaryOutcomes measure: Health related quality of life improvement through parent questionnaire, eligibilityModule sex: ALL, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: ASST Fatebenefratelli Sacco (PO "V. Buzzi"), status: RECRUITING, city: Milan, state: MI, zip: 20154, country: Italy, contacts name: Sara Olivotto, MD, role: CONTACT, email: sara.olivotto@asst-fbf-sacco.it, contacts name: Roberto Previtali, MD, role: CONTACT, email: roberto.previtali@unimi.it, geoPoint lat: 45.46427, lon: 9.18951, locations facility: Fondazione "Istituto Neurologico Nazionale C. Mondino", status: RECRUITING, city: Pavia, state: PV, zip: 27100, country: Italy, contacts name: Valentina De Giorgis, MD, role: CONTACT, email: valentina.degiorgis@mondino.it, contacts name: Carlo Alberto Quaranta, MD, role: CONTACT, email: carloalberto.quaranta01@universitadipavia.it, geoPoint lat: 45.19205, lon: 9.15917, locations facility: Ospedale Pediatrico Bambino Gesù, status: RECRUITING, city: Roma, state: RM, zip: 00165, country: Italy, contacts name: Antonella Diamanti, MD, role: CONTACT, email: antonella.diamanti@opbg.net, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06309225, orgStudyIdInfo id: BMDA-2301, briefTitle: Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly, acronym: (DACHOC-E), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2026-03-01, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Omar Mahmoud, class: OTHER, descriptionModule briefSummary: Previous studies of this type of head and necl cancer have shown high rates of cancer control but result in many short and long term side effects when treated with high dose radiation and chemotherapy. Recently, investigators have noticed similar high rates of cancer control in small numbers of patients who receive less intensive treatments using lower doses of radiation, smaller radiation fields with chemotherapy. It is expected that the side effects of treatment with lower doses of radiation would be less.For this reason this study is looking at a different regimen of reducing the intensity of the treatment.The purpose of this study is to compare any good and bad effects of using lower dose smaller fields radiation therapy and chemotherapy with published outcomes. This study will allow the researchers to know whether these different approaches are better, the same, or worse than the usual approach. To be better, the study approach should result in the same survival rate of the usual approach (about 85 out of 100 patients alive and free of cancer at 2 years) but with less long-term side effects., conditionsModule conditions: Oropharynx Cancer, conditions: Frailty, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Modified dose and fields intensity modulated radiotherapy, outcomesModule primaryOutcomes measure: Two-year progression free survival, secondaryOutcomes measure: Benefit and Tolerance of Treatment, secondaryOutcomes measure: Acute Toxicity, secondaryOutcomes measure: Late toxicity, secondaryOutcomes measure: Failure pattern, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 99 Years, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06309212, orgStudyIdInfo id: 2023-20/687, briefTitle: Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-12-15, primaryCompletionDateStruct date: 2023-12-30, completionDateStruct date: 2024-01-30, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Acibadem University, class: OTHER, descriptionModule briefSummary: Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey., conditionsModule conditions: The Prevalance of HMPV After COVID-19 Pandemic, conditions: The Importance of Accurate Diagnosis for HPMV, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 2197, type: ACTUAL, armsInterventionsModule interventions name: Observation, outcomesModule primaryOutcomes measure: Prevalence of HMPV infection in adults pre- and post-COVID-19 pandemic, secondaryOutcomes measure: Comparison of HMPV with other respiratory viruses in adults, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Acibadem University, city: Istanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06309199, orgStudyIdInfo id: 0855/66, briefTitle: Prevalence of FGIDs and Probiotics Study, acronym: PROOF, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-02, completionDateStruct date: 2026-02, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Chulalongkorn University, class: OTHER, descriptionModule briefSummary: This is a study to evaluate the prevalence of FGIDs in infants using the Thai version of Rome IV diagnostic questionnaire for functional gastrointestinal disorders in infants and evaluate the efficacy of Limosilactobacillus reuteri DSM 17938 to prevent FGIDs in infants., conditionsModule conditions: Functional Gastrointestinal Disorders, conditions: Infant Conditions, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Intervention group received probiotics Control group received sunflower and MCT oil, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: These 2 groups was assigned using computer generate with block of 4 and ratio 1:1.The intervention and placebo were prepare in the same container with the same color, odor and blinded to investigators, participants and guardians., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 512, type: ESTIMATED, armsInterventionsModule interventions name: Biogaia, interventions name: Placebo, outcomesModule primaryOutcomes measure: The prevalence of functional gastrointestinal disorders in the treatment group, secondaryOutcomes measure: The prevalence of functional gastrointestinal disorders in the placebo group, otherOutcomes measure: Nutrition associated with functional gastrointestinal disorders in infants, otherOutcomes measure: Gut microbial profiles associated with functional gastrointestinal disorder in infants, otherOutcomes measure: The sleep quality assessed by Brief Infant Sleep Revise Questionnaire of BISQR, otherOutcomes measure: Stool metabolomic substances (i.e microbial conjugation of secondary bile acid, aminoacid) and the stool metabolites alteration, otherOutcomes measure: Fluid intake associated with functional gastrointestinal disorders in infants, otherOutcomes measure: Stress associated with functional gastrointestinal disorders in infants, otherOutcomes measure: Antibiotics associated with functional gastrointestinal disorders in infants, otherOutcomes measure: Economic status associated with functional gastrointestinal disorders in infants, otherOutcomes measure: Education of caregiver associated with functional gastrointestinal disorders in infants, eligibilityModule sex: ALL, minimumAge: 3 Days, maximumAge: 1 Year, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06309186, orgStudyIdInfo id: RC 30/2023, briefTitle: Empowerment and Burnout of Midwives at the End of Health Emergency From COVID-19, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-09, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-13, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: IRCCS Burlo Garofolo, class: OTHER, descriptionModule briefSummary: As the fifth wave of COVID-19 comes to an end and the pandemic's countermeasures expire, there is a need to assess the impact of the pandemic on health care providers, especially midwives, as the professionals deputed to promote and protect women's holistic health, in all phases, physiological and otherwise, of the life cycle. The midwife considers the person as a whole, in which the mind-body-culture components interact profoundly. Prevention and containment measures have impacted on midwifery clinical and nursing practices with the mandatory continuous use of personal protective equipments (PPE) and social distancing to protect the patient and the practitioner, effectively hindering the intimacy of the woman-midwife relationship. The impact assessment focuses on two dimensions: learning, investigated as perceived empowerment, and perceived malaise, investigated as burnout. Empowerment has a positive connotation, which can offset burnout, a syndrome that affects the physical, psychological and emotional health of midwives and can have significant negative implications on midwife turnover, patient safety and outcomes, and the efficiency of healthcare organisations., conditionsModule conditions: COVID-19, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Evaluation of midwifes' burnout, outcomesModule primaryOutcomes measure: Evaluation of empowerment of midwives, primaryOutcomes measure: Number of midwives affected by burnout, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", status: RECRUITING, city: Trieste, zip: 34137, country: Italy, contacts name: Martina Debelli, role: CONTACT, email: martina.debelli@burlo.trieste.it, geoPoint lat: 45.64953, lon: 13.77679, hasResults: False